These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25702360)

  • 1. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
    Hogan DB
    Can J Psychiatry; 2014 Dec; 59(12):618-23. PubMed ID: 25702360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.
    Hogan DB
    Can J Psychiatry; 2015 Jul; 60(7):338. PubMed ID: 26175396
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
    Charbonneau C; Massoud F; Dorais M; LeLorier J
    Curr Med Res Opin; 2008 Dec; 24(12):3287-94. PubMed ID: 19032117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
    Herrmann N; O'Regan J; Ruthirakuhan M; Kiss A; Eryavec G; Williams E; Lanctôt KL
    J Am Med Dir Assoc; 2016 Feb; 17(2):142-7. PubMed ID: 26482056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
    Renn BN; Asghar-Ali AA; Thielke S; Catic A; Martini SR; Mitchell BG; Kunik ME
    Am J Geriatr Psychiatry; 2018 Feb; 26(2):134-147. PubMed ID: 29167065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based study of cholinesterase inhibitor use for dementia.
    Herrmann N; Gill SS; Bell CM; Anderson GM; Bronskill SE; Shulman KI; Fischer HD; Sykora K; Shi HS; Rochon PA
    J Am Geriatr Soc; 2007 Oct; 55(10):1517-23. PubMed ID: 17697100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
    Franchi C; Lucca U; Tettamanti M; Riva E; Fortino I; Bortolotti A; Merlino L; Pasina L; Nobili A
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):497-505. PubMed ID: 21432941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
    Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
    Wattmo C; Wallin ÅK; Londos E; Minthon L
    Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.
    Thorpe L
    Can J Psychiatry; 2015 Jul; 60(7):338. PubMed ID: 26175397
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy of Alzheimer disease: symptomatic or neuroprotective?
    Giacobini E
    J Neural Transm Suppl; 1994; 43():211-7. PubMed ID: 7884402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease.
    Cheng YW; Chen TF; Cheng TW; Lai YM; Hua MS; Chen YF; Chiu MJ
    Alzheimers Res Ther; 2015 Nov; 7():72. PubMed ID: 26592961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching cholinesterase inhibitors in older adults with dementia.
    Massoud F; Desmarais JE; Gauthier S
    Int Psychogeriatr; 2011 Apr; 23(3):372-8. PubMed ID: 21044399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
    Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
    Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.